[go: up one dir, main page]

BR9201089A - Composto estereoisomero,formulacao farmaceutica,processo para preparar um composto - Google Patents

Composto estereoisomero,formulacao farmaceutica,processo para preparar um composto

Info

Publication number
BR9201089A
BR9201089A BR929201089A BR9201089A BR9201089A BR 9201089 A BR9201089 A BR 9201089A BR 929201089 A BR929201089 A BR 929201089A BR 9201089 A BR9201089 A BR 9201089A BR 9201089 A BR9201089 A BR 9201089A
Authority
BR
Brazil
Prior art keywords
compound
prepare
pharmaceutical formulation
stereoisomer
stereoisomer compound
Prior art date
Application number
BR929201089A
Other languages
English (en)
Inventor
Richard Nolan Booher
David Ernest Lawhorn
Charles Johnson Paget Jr
John Mehnert Schaus
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9201089A publication Critical patent/BR9201089A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR929201089A 1991-03-28 1992-03-27 Composto estereoisomero,formulacao farmaceutica,processo para preparar um composto BR9201089A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/677,016 US5244912A (en) 1991-03-28 1991-03-28 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
BR9201089A true BR9201089A (pt) 1992-11-24

Family

ID=24716969

Family Applications (1)

Application Number Title Priority Date Filing Date
BR929201089A BR9201089A (pt) 1991-03-28 1992-03-27 Composto estereoisomero,formulacao farmaceutica,processo para preparar um composto

Country Status (26)

Country Link
US (1) US5244912A (pt)
EP (1) EP0506363B1 (pt)
JP (1) JP3159766B2 (pt)
KR (1) KR100221158B1 (pt)
CN (2) CN1059210C (pt)
AT (1) ATE180256T1 (pt)
AU (1) AU649319B2 (pt)
BR (1) BR9201089A (pt)
CA (1) CA2064384A1 (pt)
CS (1) CS85692A3 (pt)
DE (1) DE69229197T2 (pt)
DK (1) DK0506363T3 (pt)
ES (1) ES2133303T3 (pt)
FI (1) FI921347A (pt)
GR (1) GR3030760T3 (pt)
HK (1) HK1013824A1 (pt)
HU (1) HU217590B (pt)
IE (1) IE921001A1 (pt)
IL (1) IL101324A (pt)
MX (1) MX9201374A (pt)
MY (1) MY108450A (pt)
NO (1) NO301642B1 (pt)
NZ (1) NZ242088A (pt)
RU (1) RU2059621C1 (pt)
YU (1) YU31492A (pt)
ZA (1) ZA922070B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364856A (en) * 1991-03-28 1994-11-15 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles
US5244911A (en) * 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz(cd)indoles and pharmaceutical use thereof
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
NZ260667A (en) * 1993-06-10 1997-05-26 Lilly Co Eli Preventing emesis or treating sexual dysfunction using tetrahydrobenz[cd]indole 6-carboxamides
US5385928A (en) * 1994-05-18 1995-01-31 Eli Lilly And Company Tetrahydrobenz [CD] indazoles, compositions and use
WO1995032965A1 (fr) * 1994-06-01 1995-12-07 Yamanouchi Pharmaceutical Co. Ltd. Derive de l'oxadiazole et composition medicinale a base de ce dernier
FR2732964B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux amides tricycliques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
TW430660B (en) * 1996-05-30 2001-04-21 Mochida Pharm Co Ltd Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
CA2319174A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
EP3581576B1 (en) 2013-03-15 2022-01-26 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors for use in the treatment of a proliferative disease in combination with a janus kinase inhibitor
US9290514B2 (en) 2013-07-08 2016-03-22 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
TWI735002B (zh) 2014-04-23 2021-08-01 美商英塞特公司 作為BET蛋白抑制劑之1H-吡咯并[2,3-c]吡啶-7(6H)-酮及吡唑并[3,4-c]吡啶-7(6H)-酮
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
TWI786050B (zh) 2016-06-20 2022-12-11 美商英塞特公司 Ｂｅｔ抑制劑之結晶固體形式
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE517732C (de) * 1927-10-27 1931-02-09 Then Rudolf Faerbekufe mit einem drehbaren, trommelartigen Rahmen fuer die auf aus-wechselbaren Faerbestoecken aufgehaengten Waren, insbesondere Struempfe
US3194811A (en) * 1963-09-05 1965-07-13 Merck & Co Inc Aroyl-benzindolyl acids
BE755270A (fr) * 1969-08-27 1971-02-25 Sandoz Sa Nouveaux derives du benzo(cd)indole, leur preparation et medicaments contenant ces derives
BE757879A (fr) * 1969-10-24 1971-04-22 Sandoz Sa Derives du benzo(cd)indole, leur preparation et medicaments contenant ces derives
FI206974A (pt) * 1973-07-16 1975-01-17 Sandoz Ag
US4110339A (en) * 1977-11-25 1978-08-29 Eli Lilly And Company 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
US4282240A (en) * 1979-11-23 1981-08-04 Merck & Co., Inc. Amino substituted tetrahydrobenzindoles
FR2510111A1 (fr) * 1981-07-24 1983-01-28 Roussel Uclaf Nouveaux derives du piperidin-3-yl indole, leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
FR2522658A1 (fr) * 1982-03-05 1983-09-09 Roussel Uclaf Application a titre de medicaments de derives du trans 4-amino benz (c,d) indol-5-ol ainsi que de leurs sels, compositions les renfermant, nouveaux derives et leur procede de preparation
DE3346573A1 (de) * 1983-12-23 1985-07-04 Troponwerke GmbH & Co KG, 5000 Köln 1,3,4,5-tetrahydrobenz(c,d)indole, ein verfahren zu ihrer herstellung und ihre verwendung
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
IL74222A (en) * 1984-02-06 1988-07-31 Lilly Co Eli 6-substituted-4-dialkylamino tetrahydrobenz(c,d)indoles,their preparation and pharmaceutical compositions comprising them
US4576959A (en) * 1984-02-06 1986-03-18 Eli Lilly And Company 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles
CA1266482A1 (en) * 1984-05-24 1990-03-06 Carl Kaiser 6-oxygenated-1,3,4,5-tetrahydrobenz(cd)indol-4-amines
DE3525564A1 (de) * 1985-07-15 1987-02-05 Schering Ag Tricyclische verbindungen mit indolstruktur, verfahren zu ihrer herstellung und deren verwendung als arzneimittel
US4745126A (en) * 1987-03-12 1988-05-17 Eli Lilly And Company Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides
DE3809155A1 (de) * 1988-03-18 1989-09-28 Bayer Ag 1,3,4,5-tetrahydrobenz-(c,d)-indole
SE8901889D0 (sv) * 1989-05-26 1989-05-26 Astra Ab Novel 8-substituted-2-aminotetralines
US5244911A (en) * 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz(cd)indoles and pharmaceutical use thereof

Also Published As

Publication number Publication date
MX9201374A (es) 1992-10-01
ZA922070B (en) 1993-09-20
EP0506363B1 (en) 1999-05-19
AU649319B2 (en) 1994-05-19
FI921347A0 (fi) 1992-03-27
MY108450A (en) 1996-09-30
HU217590B (hu) 2000-02-28
KR100221158B1 (ko) 1999-09-15
EP0506363A1 (en) 1992-09-30
DE69229197D1 (de) 1999-06-24
NO921128D0 (no) 1992-03-23
DK0506363T3 (da) 1999-11-08
US5244912A (en) 1993-09-14
YU31492A (sh) 1994-09-09
CN1066072A (zh) 1992-11-11
IL101324A0 (en) 1992-11-15
IE921001A1 (en) 1992-10-07
FI921347A (fi) 1992-09-29
IL101324A (en) 1996-07-23
NZ242088A (en) 1994-09-27
GR3030760T3 (en) 1999-11-30
KR920018043A (ko) 1992-10-21
CN1268352A (zh) 2000-10-04
CN1059210C (zh) 2000-12-06
JPH0597849A (ja) 1993-04-20
NO301642B1 (no) 1997-11-24
HU9201015D0 (en) 1992-06-29
AU1382692A (en) 1992-10-01
ATE180256T1 (de) 1999-06-15
CS85692A3 (en) 1992-10-14
HUT62878A (en) 1993-06-28
NO921128L (no) 1992-09-29
ES2133303T3 (es) 1999-09-16
RU2059621C1 (ru) 1996-05-10
DE69229197T2 (de) 1999-10-14
CA2064384A1 (en) 1992-09-29
HK1013824A1 (en) 1999-10-15
JP3159766B2 (ja) 2001-04-23

Similar Documents

Publication Publication Date Title
BR9201089A (pt) Composto estereoisomero,formulacao farmaceutica,processo para preparar um composto
MX9102582A (es) Derivados de indol 3,7-disubstituidos, procedimiento para su preparacion y composicion farmaceutica que los contiene.
PT84075B (pt) Processo para a preparacao de derivados de indol
NO943762L (no) Indolderivater som 5-HT 1 agonister
PT100041A (pt) Processo para a preparacao de derivados de indol e de composicoes farmaceuticas que os contem
BR9201083A (pt) Composto,estereoisomero,formulacao farmaceutica e processo para a preparacao de um composto
BR9302427A (pt) Processo estereo seletivo para a preparacao de um derivado de riboturanosila
BR9200627A (pt) Processo para a preparacao de um composto e composto obtido
BR9103481A (pt) Composto,estereoisomero,composicao farmaceutica e processo para preparar um composto
PT90212A (pt) Processo aperfeicoado para a preparacao de derivados de 3-fenoloxi-3-fenil-propanaminas
BR9100769A (pt) Composto,estereoisomero,formulacao farmaceutica,processo para a preparacao de um composto
PT96088A (pt) Processo para a preparacao de compostos moluscicidas 2,4,5-tribomopirrole-3-carbonitrilo
BR9500821A (pt) Processo para a preparação de um derivado de indol
PT93714A (pt) Processo para a preparacao de tricloridrato de 1-(3-dietilamino-propil)-amino-5-metildipirido-{4,3-b}{3,4-f}indole
NO950240L (no) Fremgangsmåte for fremstilling av optisk rene aromatiske aminforbindelser

Legal Events

Date Code Title Description
EE Request for examination
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
CKFC Appeal: appeal against refusal